4. Verastem Oncology (NASDAQ:VSTM)
Verastem Oncology ranks No. 4 because it combines a penny-stock price with an FDA-approved oncology story and an active commercial base. Trading around $4.33 with a market capitalization near $429 million, VSTM is not just a biotech dream built around distant trial hopes. It has an ovarian cancer co-pack story, a pipeline tied to RAS/MAPK-driven cancers, and Q1 2026 net product revenue of $18.7 million.
In the biotech sector, oncology remains one of the most powerful areas for investor attention. Cancer treatment is a massive market, and companies working on targeted therapies can attract serious interest if they show clinical and commercial traction. Verastem’s work around RAS/MAPK-driven cancers gives it a scientific angle that investors recognize as important. The RAS/MAPK pathway has long been a major focus in cancer research because of its role in tumor growth and treatment resistance.
The $18.7 million in Q1 net product revenue gives Verastem something many small-cap oncology stocks lack: a commercial starting point. Revenue does not remove the risk, but it does separate VSTM from purely clinical-stage cancer penny stocks. Investors can now judge the company not only on pipeline promise but also on launch execution, patient access, physician adoption, and commercial growth.
That said, oncology launches are expensive. Sales teams, medical education, market access, manufacturing, and post-approval commitments can all pressure cash. The company still burns cash, which means investors need to monitor financial discipline closely. A biotech company can have an approved product and still face shareholder pressure if expenses remain high or if revenue growth does not accelerate fast enough.
For June, VSTM checks several important SEO and investment boxes: “oncology penny stock,” “FDA-approved biotech stock,” “NASDAQ cancer stock under $5,” “small-cap biotech with revenue,” and “biotech stock with commercial launch potential.” It has more substance than a typical speculative penny stock, but it still carries enough risk to remain volatile.
Verastem earns the No. 4 ranking because it has a rare combination: penny-stock pricing, oncology relevance, FDA-approved commercial activity, and an active pipeline. It is not risk-free, but among biotech penny stocks to watch this June, it has enough real-world business progress to deserve serious attention.
Click next to see the following stock...
